JP MORGAN/PUT/VERTEX PHARMACEUTICALS/370/0.1/19.07.24

JP MORGAN/PUT/VERTEX PHARMACEUTICALS/370/0.1/19.07.24 Share Price

Warrant

DE000JB7WPU2

Delayed Börse Stuttgart 11:07:05 20/06/2024 BST
0.01 ^EUR	-28.57%

1 month	-90.00%
3 months	-99.03%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/PUT/VERTEX PHARMACEUTICALS/370/0.1/19.07.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	07-02	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	07-02	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	CI

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JB7WPU
ISIN	DE000JB7WPU2
Date issued	18/12/2023
Strike	370 $
Maturity	19/07/2024 (15 Days)
Parity	10 : 1
Emission price	1.34 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	1.92 €
Lowest since issue	0.009 €
Spread	0.5 €
Spread %	98.04%

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company